GlaxoSmithKline plc (GSK.L)
- Reuters
China's Clover says its coronavirus vaccine candidate showed promise in animal test
An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said. The result of the study on monkeys comes months after Clover began an early stage human trial in Australia in June, as global drug makers race to develop a safe and effective vaccine that can protect people from the COVID-19 pandemic that has killed nearly 1 million people. Clover's vaccine candidate, which is partly funded by a global vaccine research coalition, uses adjuvants, ingredients that could boost immune responses, from Britain's GlaxoSmithKline and U.S.-based Dynavax Technologies.
- Zacks
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
- Zacks
Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada
Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
